Titre du document / Document title

Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori : A randomized, controlled trial

Auteur(s) / Author(s)

OHKUSA T. ⁽¹⁾ ; TAKASHIMIZU I. ⁽¹⁾ ; FUJIKI K. ⁽¹⁾ ; SUZUKI S. ⁽¹⁾ ; SHIMOI K. ⁽¹⁾ ; HORIUCHI T. ⁽¹⁾ ; SAKURAZAWA T. ⁽¹⁾ ; ARIAKE K. ⁽¹⁾ ; ISHII K. ⁽¹⁾ ; KUMAGAI J. ⁽¹⁾ ; TANIZAWA T. ⁽¹⁾ ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ Tokyo Medical and Dental University School of Medicine, Tokyo, JAPON

Résumé / Abstract

Background: Helicobacter pylori infection is common in patients with hyperplastic gastric polyps. Objective: To study the effect of eradication of H. pylor, on the clinical course of patients with hyperplastic gastric polyps. Design: Single-blind, randomized, controlled trial. Setting: University-based gastroenterology outpatient clinic. Patients: 35 patients with H. pylori infection and hyperplastic gastric polyps at least 3 mm in diameter. Intervention: Patients were randomly assigned to a treatment group (n = 17), which received a proton-pump inhibitor (omeprazole or lansoprazole), amoxicillin, and either clarithromycin or ecabet sodium, or to a control group (n = 18), which received no treatment. Measurements: Patients underwent endoscopy before enrollment and 12 to 15 months after the end of treatment. Serum gastrin levels and titers of IgG to H. pylori were measured. Results: In the treatment group, the polyps had disappeared by 3 to 15 months (average, 7.1 ± 1.2 months) after the end of treatment in 12 of all 17 patients (71%) and in 12 of the 15 patients (80%) in whom H. pylori was eradicated. However, 12 to 15 months after the start of the study, no change in polyps or H. pylori status was seen in any controls (P < 0.001). Histologic findings of inflammation and activity, serum gastrin levels, and titers of IgG to H. pylori showed significant regression in the treatment group compared with the control group (P < 0.01). Conclusions: Most hyperplastic polyps disappeared after eradication of H. pylori. Thus, eradication should be attempted before endoscopic removal is done in patients with hyperplastic gastric polyps and H. pylori infection.

Revue / Journal Title

Annals of internal medicine   ISSN 0003-4819   CODEN AIMEAS 

Source / Source

1998, vol. 129, n^o9, pp. 712-715 (19 ref.)

Langue / Language

Anglais

Editeur / Publisher

American College of Physicians, Philadelphia, PA, ETATS-UNIS  (1927) (Revue)

Mots-clés anglais / English Keywords

Bacteriosis ; Helicobacter pylori ; Stomach ; Polyp ; Hyperplasia ; Cure ; Clarithromycin ; Antibiotic ; Antibacterial agent ; Amoxicillin ; Evolution ; Endoscopy ; Omeprazole ; Treatment ; Chemotherapy ; Antiulcer agent ; Antisecretory agent ; Enzyme inhibitor ; Randomization ; Controlled therapeutic trial ; Macrolide ; Penicillin derivatives ; β-Lactams ; Benzimidazole derivatives ; Infection ; Spirillaceae ; Spirillales ; Bacteria ;

Mots-clés français / French Keywords

Bactériose ; Helicobacter pylori ; Estomac ; Polype ; Hyperplasie ; Guérison ; Clarithromycine ; Antibiotique ; Antibactérien ; Amoxicilline ; Evolution ; Endoscopie ; Oméprazole ; Traitement ; Chimiothérapie ; Antiulcéreux ; Antisécrétoire ; Inhibiteur enzyme ; Randomisation ; Essai thérapeutique contrôlé ; Macrolide ; Pénicilline dérivé ; β-Lactamines ; Benzimidazole dérivé ; Infection ; Spirillaceae ; Spirillales ; Bactérie ;

Mots-clés espagnols / Spanish Keywords

Bacteriosis ; Helicobacter pylori ; Estómago ; Pólipo ; Hiperplasia ; Curación ; Claritromicina ; Antibiótico ; Antibacteriano ; Amoxicilina ; Evolución ; Endoscopía ; Omeprazol ; Tratamiento ; Quimioterapia ; Antiulceroso ; Antisecretorio ; Inhibidor enzima ; Aleatorización ; Ensayo terapéutico controlado ; Macrólido ; Penicilinas ; β-Lactams ; Benzimidazol derivado ; Infección ; Spirillaceae ; Spirillales ; Bacteria ;

Localisation / Location

INIST-CNRS, Cote INIST : 2014, 35400007190995.0050